
GPS reduced the risk of death by 41% versus best available treatment, and SELLAS plans FDA discussions and BLA preparations.
SELLAS Life Sciences said its Phase 3 REGAL trial met its primary endpoint, with its investigational vaccine GPS showing a statistically significant improvement in overall survival for some patients with acute myeloid leukemia. The company reported a 41% lower risk of death compared with best available treatment.
Median overall survival was 24.0 months for patients receiving GPS and 14.7 months for those receiving best available treatment. The result had a hazard ratio of 0.59 and a two-sided p-value of 0.035.
The company said GPS was generally well tolerated, with no new safety signals. SELLAS plans to meet with the FDA to discuss an accelerated filing strategy and prepare a Biologics License Application submission in the first half of 2027.
This article was produced with the help of AI technology. Based on reporting by the outlets listed above.